Environ Toxicol Pharmacol. 1996 Oct 15;2(2-3):207-12. doi: 10.1016/S1382-6689(96)00057-9.
In vitro data could make an important contribution to the application of the proposed scheme for the subdivision of the usual 10-fold safety factors (used in risk assessment for inter-species and inter-individual differences) into two separate aspects of toxicokinetics and toxicodynamics. Whereas toxicokinetics (or delivery of the chemical to its site of action via the general circulation) is amenable to direct in vivo measurement, toxicodynamics (or the assessment of the sensitivity of the target tissue to the presence of the chemical) is open to in vitro investigation. Human risk assessment requires human data to be able to replace any of the default safety (or uncertainty) factors (Renwick, 1993). Because human tissues are of limited availability, it is likely that the main quantitative contribution of in vitro data will be to allow chemical specific inter-species differences in toxicodynamics to replace the proposed default value. Although in vitro data from human tissues could be used to define human variability in target organ sensitivity (toxicodynamics) this would require a large number of specimens and the variability detected in vitro should be representative of that present in vivo.
体外数据可能会为应用所提出的方案做出重要贡献,该方案将通常的 10 倍安全系数(用于评估种间和个体间差异的风险)细分为毒代动力学和毒效动力学两个独立方面。虽然毒代动力学(或通过体循环将化学物质输送到其作用部位)可进行直接体内测量,但毒效动力学(或评估靶组织对化学物质存在的敏感性)可进行体外研究。人类风险评估需要使用人类数据来替代任何默认的安全(或不确定性)因素(Renwick,1993 年)。由于人类组织的可用性有限,因此体外数据的主要定量贡献可能是允许毒效动力学中特定于化学物质的种间差异来替代拟议的默认值。尽管可以使用来自人类组织的体外数据来定义靶器官敏感性(毒效动力学)方面的人类变异性,但这需要大量样本,并且体外检测到的变异性应代表体内存在的变异性。